400
Participants
Start Date
February 1, 2019
Primary Completion Date
December 31, 2022
Study Completion Date
December 31, 2024
Electronic alert
"On-screen electronic alert that notifies the provider about the increased risk for VTE after discharge and indication for thromboprophylaxis will be issued 48 hours after admission. This first on-screen electronic alert will provide the clinician with the opportunity to consider extended-duration, post-discharge thromboprophylaxis and start any required processes for prior authorization or medication coverage. The provider then will be given on-screen options to either order thromboprophylaxis (betrixaban or low-molecular weight heparin for 35 days) from a Extended-Duration VTE Prevention order template, follow a link to evidence-based practice guidelines, or defer prescribing extended-duration, post-discharge thromboprophylaxis."
RECRUITING
Brigham and Women's Hospital, Boston
Collaborators (1)
Portola Pharmaceuticals
INDUSTRY
Brigham and Women's Hospital
OTHER